Emergency Medicine Pharmacist Prescriptive Authority for Resolution of Outpatient Prescription Issues

Emergency Medicine Pharmacist Prescriptive Authority for Resolution of Outpatient Prescription Issues: A Descriptive Study

The study aims to document the utility of Methodist Charlton Medical Center (MCMC's)Emergency Medicine Pharmacist (EMP) Collaborative Practice Agreement (CPA )utilization for the resolution of outpatient prescription issues. Evaluation of utility will involve describing all EMP-written prescriptions pursuant to resolution of prescription issues realized after discharge.

Study Overview

• Status: Completed
• Conditions: Outpatient Prescription Issues
• Intervention / Treatment: Other: outpatient prescription issues

Detailed Description

Use of an EMP CPA, which allows for broad prescriptive authority, will assist Emergency Department (ED )workflow by preventing a significant volume of new prescriptions needing to be sent by physician and mid-level providers. Will improve rates of ED re-visits. In addition, this Collaborative Practice Agreement (CPA) will not be associated with a large volume of new prescription errors.

• Study Type: Interventional
• Enrollment (Actual): 350
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Texas
    • Dallas, Texas, United States, 75203
      • Clinical Research Institute at Methodist Health System

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients at MCMC who had a prescription sent by an EMP between November 1, 2021 and June 30, 2023 and a progress note and documenting the reason for the call and action taken by the EMP.

Exclusion Criteria:

• CPA actions were misclassified as discharge prescription issue resolutions.
• Patients with prescriptions pursuant to late culture review, formulation changes not requiring a new prescription, prescription transfers to another pharmacy, or simple retransmission of prescriptions.
• Patients documented to have left the ED against medical advice.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Patients at MCMC who had a prescription sent by an EMP between November 1, 2021 and June 30, 2023; Evaluation of utility will involve describing all EMP-written prescriptions pursuant to resolution of prescription issues realized after discharge.	Other: outpatient prescription issues; Evaluation of utility will involve describing all Emergency Medicine Pharmacist (EMP)-written prescriptions pursuant to resolution of prescription issues realized after discharge

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of prescriptions and medication types sent to outpatient pharmacies	Number of prescriptions and medication types sent to outpatient pharmacies by EMPs pursuant to outpatient prescription issue resolution.	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients returning with complaint or diagnosis related to EMP generated prescriptions	Proportion of patients returning with a complaint or diagnosis related to index EMP-generated prescriptions at three and six-month time points	2 years

Collaborators and Investigators

• Sponsor: Methodist Health System
• Investigators: Principal Investigator: Kevin Burnham, Pharm.D., Methodist Health System

Study record dates

Study Major Dates

• Study Start (Actual): December 15, 2023
• Primary Completion (Actual): March 1, 2026
• Study Completion (Actual): March 15, 2026

Study Registration Dates

• First Submitted: January 16, 2024
• First Submitted That Met QC Criteria: January 16, 2024
• First Posted (Actual): January 24, 2024

Study Record Updates

• Last Update Posted (Actual): March 23, 2026
• Last Update Submitted That Met QC Criteria: March 19, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Emergencies
• Other Study ID Numbers: 045.PHA.2023.C

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No